EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access

Effects of MAO ‐B Inhibitors on Cognition in Patients with Parkinson's Disease: A Systematic Network Meta‐Analysis

Seon-Min Lee, Sung Ryul Shim, Yu Jin Jung, Taeho Greg Rhee, Kyum-Yil Kwon

Movement Disorders Clinical Practice · 2026-06 · 13 (6) · 1468-1478

DOI: 10.1002/mdc3.70520 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 12.01.2026. Verfasst von Seon-Min Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Konyang University College of Medicine, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Monoamine Oxidase Inhibitors, Cognition, Cognitive Dysfunction. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Konyang University Myunggok Research Fund of 2023, Soonchunhyang University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD) is a neurodegenerative disorder accompanied by cognitive impairment, which increases a risk of dementia as the condition progresses. Although monoamine oxidase B (MAO‐B) inhibitors, such as selegiline, rasagiline and safinamide, are used to treat motor symptoms in PD, their impacts on cognitive performance remain unclear.

Objectives

This study systematically evaluated and compared the impacts of MAO‐B inhibitors on global cognitive performance and performance of individual cognitive domains in patients with PD.

Methods

Databases were searched through PubMed/Medline, Embase, and Cochrane Library from the inception to May 30, 2025. Thirteen randomized controlled trials (RCTs) evaluating cognitive outcomes in patients with PD treated with selegiline, rasagiline or safinamide were included. Standardized mean differences (SMDs) for global cognition and five cognitive sub‐domains were pooled, respectively, using random‐effects models. Publication bias and methodological quality were also assessed.

Results

13 RCTs met inclusion criteria. Network meta‐analysis showed that only rasagiline significantly improved global cognition compared to placebo (SMD, 0.863; 95% CI, 0.064–1.663), whereas selegiline and safinamide did not show any statistical difference when compared to placebo. None of the MAO‐B inhibitors demonstrated significant effects on specific cognitive sub‐domains (ie, attention, executive function, memory, language, and visuospatial abilities).

Conclusions

Rasagiline may provide global cognitive benefits in PD, but MAO‐B inhibitors, including rasagiline, generally did not demonstrate significant effects on individual cognitive domains. These findings suggest limited cognitive impacts of MAO‐B inhibitors beyond managing the motor symptoms. Further large‐scale, long‐term studies using domain‐specific cognitive assessments are warranted to clarify their roles in cognitive performance in patients with PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseMonoamine Oxidase InhibitorsCognitionCognitive DysfunctionHumansIndansSelegilineBenzylaminesCognitive EnhancementRandomized Controlled Trials as TopicAlanine

Stichwörter der Autor:innen

MAOB inhibitorParkinson's diseaseRasagilineSelegilinecognitionsafinamide

Substanzen

Monoamine Oxidase InhibitorsIndansSelegilinerasagilineBenzylaminessafinamideAlanine

Autor:innen und Institutionen

  • Department of Neurology, Konyang University College of Medicine, Daejeon, Republic of Korea.
  • Myunggok Medical Research Institute, Konyang University College of Medicine, Daejeon, Republic of Korea.
  • Department of Biomedical Informatics, Konyang University College of Medicine, Daejeon, Republic of Korea.
  • Evidence Based Research Center, Konyang University Hospital, Daejeon, Republic of Korea.
  • Department of Neurology, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
  • Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.

Förderung

  • Konyang University Myunggok Research Fund of 2023
  • Soonchunhyang University

Zitieren

APA

Lee, S. M., Shim, S. R., Jung, Y. J., Rhee, T. G., & Kwon, K. Y. (2026). Effects of MAO ‐B Inhibitors on Cognition in Patients with Parkinson's Disease: A Systematic Network Meta‐Analysis. Movement Disorders Clinical Practice, 13(6), 1468-1478. https://doi.org/10.1002/mdc3.70520

Vancouver

Lee SM, Shim SR, Jung YJ, Rhee TG, Kwon KY. Effects of MAO ‐B Inhibitors on Cognition in Patients with Parkinson's Disease: A Systematic Network Meta‐Analysis. Movement Disorders Clinical Practice. 2026;13(6):1468-1478. doi:10.1002/mdc3.70520

BibTeX
@article{Lee2026,
  author = {Lee, Seon-Min and Shim, Sung Ryul and Jung, Yu Jin and Rhee, Taeho Greg and Kwon, Kyum-Yil},
  title = {Effects of MAO ‐B Inhibitors on Cognition in Patients with Parkinson's Disease: A Systematic Network Meta‐Analysis},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1468--1478},
  doi = {10.1002/mdc3.70520}
}
Kostenlos starten →